Characteristics of neutrophils in patient groups and healthy controls.

<p>Phagocytic capacity of neutrophils (a), proportion of inactive neutrophils (b) and PMN elastase levels per 10⁶neutrophils (c) of patients and controls. Ctrl: healthy controls; TPV: telaprevir group; BOC: boceprevir Group; P/R: Dual therapy with peginterferon/ribavirin; B: baseline; 4w: 4 weeks of therapy; 12w: 12 weeks of therapy; F: follow up a: p = 0.021 vs Ctrl; b: p = 0.010 vs Ctrl.</p

Flow diagram of the study progress.

<p>Flow diagram of the study progress.</p

Patient and infection characteristics for 108 retrospectively analysed patients during hepatitis C therapy.

<p>Patient and infection characteristics for 108 retrospectively analysed patients during hepatitis C therapy.</p

Evenness and diversity of gut microbiota in MetS and healthy controls.

<p>MetS: metabolic syndrome.</p><p>Data are given as median (quartiles).</p

Flow diagram of the study progress.

<p>Flow diagram of the study progress.</p

Gut microbiota composition in MetS patients and controls.

<p><i>Bacteroidetes</i>/<i>Firmicutes</i> ratio (a) PCoA Plot (Weighted UniFrac, b) and abundance of <i>Parabacteroides</i> (c) concerning <i>Lc</i>S supplementation.</p

Patient characteristics.

<p>*p<0.05</p><p>**p<0.01</p><p>***p<0.001 compared to the other groups at baseline</p><p>n.a. not available; EOS: end of study; base: baseline; healthy: healthy controls.</p><p>Data are given as mean±SD.</p